MLYSMineralys Therapeutics, Inc.

Healthcare
$20.54-52% 1Y

Price

-52%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 18% of companies
17/100
Scroll down to see the criteria

The five questions

2 of 5 available

Only two of the five can be answered for MLYS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).

In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR

P/En/a
Market value$1.82B
1 year-52%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Oct 19, 2026On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.Director or officer change · Form 8-K
  2. Aug 11, 2026On August 5, 2026, the Company’s Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company’s new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor.Earnings release · Form 8-K
  3. Jun 3, 2026On June 3, 2026, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C. (the “Underwriters”), relating to the issuance and sale of 5,660,378 shares of the Company’s …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

Biotechnology

Ranks #48 of 194 by RyuScore

Compare peers
PVLA-1.0%
Palvella Therapeutics, Inc.
TRVI-2.6%
Trevi Therapeutics, Inc.
VIR+1.4%
Vir Biotechnology, Inc.
SRPT-2.5%
Sarepta Therapeutics, Inc.
XNCR-2.7%
Xencor, Inc.
ZBIO-4.9%
Zenas BioPharma, Inc.